Comparative Pharmacology

Head-to-head clinical analysis: AZITHROMYCIN versus WYAMYCIN S.

Peer-Reviewed Evidence

Differential Analysis

AZITHROMYCIN vs WYAMYCIN S

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

AZITHROMYCIN

Macrolide Antibiotic

Category A/B

WYAMYCIN S

Macrolide Antibiotic

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting mRNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.

WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.

Clinical Dosing

500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.

WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.

Direct Interaction

None Documented

Other Significant Interactions

Clinical Note

moderate

Azithromycin + Norfloxacin

"Azithromycin may increase the QTc-prolonging activities of Norfloxacin."

Clinical Note

moderate

Azithromycin + Ibandronate

"Azithromycin may increase the QTc-prolonging activities of Ibandronate."

Clinical Note

moderate

Azithromycin + Indapamide

"Azithromycin may increase the QTc-prolonging activities of Indapamide."

Clinical Note

moderate

Azithromycin + Artesunate

"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azithromycin resulting in a loss in efficacy."